The combination of the PCSK9 inhibitor with the anti-CD137 agonist led to greater tumor volume control at 21 days after inoculation from day 5 (baseline prior to antibody injection) compared with the two single groups (Figures 4E, F). This evidence concerns the gene TNFRSF9 and neoplasm.